KAEF.JK
PT Kimia Farma (Persero) Tbk [KAEF.JK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
KAEF.JK Stock Summary
In the News
KAEF.JK Financial details
Company Rating
Neutral
Market Cap
4982.04B
Income
-81.9B
Revenue
10187.72B
Book val./share
1447.63
Cash/share
2062.66
Dividend
-
Dividend %
-
Employees
11.56K
Optionable
No
Shortable
Yes
Earnings
15 Apr 2024
P/E
-78.41
Forward P/E
-
PEG
6.17
P/S
0.69
P/B
-
P/C
0.41
P/FCF
-6.04
Quick Ratio
-
Current Ratio
-
Debt / Equity
0.99
LT Debt / Equity
0.12
-
-
EPS (TTM)
-14.69
EPS next Y
-
EPS next Q
-
EPS this Y
-131.2%
EPS next Y
-
EPS next 5Y
-269.5%
EPS last 5Y
NAN%
Revenue last 5Y
5.2%
Revenue Q/Q
4.77%
EPS Q/Q
602.76%
-
-
-
-
SMA20
14.2%
SMA50
-16.49%
SMA100
20.48%
Inst Own
-
Inst Trans
-
ROA
-1%
ROE
-1%
ROC
0.07%
Gross Margin
38%
Oper. Margin
7%
Profit Margin
-1%
Payout
-22%
Shs Outstand
5.57B
Shs Float
267.88M
-
-
-
-
Target Price
-
52W Range
685.0-1935.0
52W High
-56.07%
52W Low
+24.09%
RSI
48.49
Rel Volume
0.3
Avg Volume
5.78M
Volume
1.74M
Perf Week
-7.61%
Perf Month
2.41%
Perf Quarter
-
Perf Half Y
11.84%
-
-
-
-
Beta
0.193
-
-
Volatility
27.99%, 63.88%
Prev Close
-5.03%
Price
850
Change
-0.58%
KAEF.JK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.34K | 1.69K | 1.8K | 2.32K | 1.73K | |
| Net income per share | 74.88 | 2.86 | 3.18 | 54.42 | -16.98 | |
| Operating cash flow per share | 0 | -333.78 | 183.47 | -40.32 | 23.64 | |
| Free cash flow per share | -189.24 | -474.02 | 84.7 | -159.02 | -83.78 | |
| Cash per share | 153.95 | 17.19 | 5.15 | -61.07 | 192.48 | |
| Book value per share | 576.52 | 1.3K | 1.26K | 1.29K | 1.43K | |
| Tangible book value per share | 595.97 | 1.3K | 1.24K | 1.26K | 1.64K | |
| Share holders equity per share | 576.52 | 1.3K | 1.26K | 1.29K | 1.43K | |
| Interest debt per share | 761.06 | 1.58K | 1.5K | 1.55K | 1.55K | |
| Market cap | 14440.4B | 6942.5B | 23604.5B | 13496.22B | 6026.09B | |
| Enterprise value | 16519.99B | 13878.89B | 30115.45B | 20771.68B | 11986.3B | |
| P/E ratio | 34.72 | 436.9 | 1.34K | 44.65 | -63.89 | |
| Price to sales ratio | 1.94 | 0.74 | 2.36 | 1.05 | 0.63 | |
| POCF ratio | 0 | -3.74 | 23.16 | -60.27 | 45.9 | |
| PFCF ratio | -13.74 | -2.64 | 50.18 | -15.28 | -12.95 | |
| P/B Ratio | 4.51 | 0.96 | 3.38 | 1.89 | 0.76 | |
| PTB ratio | 4.51 | 0.96 | 3.38 | 1.89 | 0.76 | |
| EV to sales | 2.22 | 1.48 | 3.01 | 1.62 | 1.25 | |
| Enterprise value over EBITDA | 19.61 | 22.98 | 36.86 | 16.9 | 15.08 | |
| EV to operating cash flow | 0 | -7.49 | 29.55 | -92.76 | 91.3 | |
| EV to free cash flow | -15.72 | -5.27 | 64.02 | -23.52 | -25.76 | |
| Earnings yield | 0.03 | 0 | 0 | 0.02 | -0.02 | |
| Free cash flow yield | -0.07 | -0.38 | 0.02 | -0.07 | -0.08 | |
| Debt to equity | 1.26 | 1.15 | 1.11 | 1.12 | 1.02 | |
| Debt to assets | 0.43 | 0.45 | 0.44 | 0.45 | 0.4 | |
| Net debt to EBITDA | 2.47 | 11.48 | 7.97 | 5.92 | 7.5 | |
| Current ratio | 1.42 | 0.99 | 0.9 | 1.05 | 1.06 | |
| Interest coverage | 4.08 | 1.01 | 1.09 | 1.62 | 1.07 | |
| Income quality | 0 | 145.7 | 57.77 | -0.74 | -1.39 | |
| Dividend Yield | 0.01 | 0.01 | 0 | 0 | 0 | |
| Payout ratio | 0.24 | 5.24 | 0 | 0 | -0.1 | |
| Sales general and administrative to revenue | 0.04 | 0.05 | 0.04 | 0.03 | 0.03 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0 | 0.42 | -0.54 | 2.94 | -4.54 | |
| Capex to revenue | -0.14 | -0.08 | -0.05 | -0.05 | -0.06 | |
| Capex to depreciation | 0 | -4.88 | -2.24 | -1.68 | -2.64 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 985.57 | 289.72 | 299.96 | 1.25K | 740.44 | |
| ROIC | 0.07 | 0.01 | 0.01 | 0.05 | -0.07 | |
| Return on tangible assets | 0.04 | 0 | 0 | 0.02 | 0 | |
| Graham Net | -603.57 | -1.27K | -1.42K | -1.42K | -1.08K | |
| Working capital | 1595.24B | -47.35B | -693.84B | 323.29B | 470.57B | |
| Tangible asset value | 3310.01B | 7199.83B | 6890.8B | 7008.32B | 9115.23B | |
| Net current asset value | -734.42B | 3595.16B | 4364.04B | 4224.85B | 2513.28B | |
| Invested capital | 1.26 | 1.15 | 1.11 | 1.12 | 1.02 | |
| Average receivables | 1127.56B | 2230.26B | 2448.18B | 1977.23B | 2682.47B | |
| Average payables | 1034.35B | 1239.95B | 1289.35B | 1037.37B | 940.87B | |
| Average inventory | 1499.04B | 2327.42B | 2652.47B | 2573.39B | 2933.95B | |
| Days sales outstanding | 64.89 | 121.74 | 64.24 | 62.27 | 120.5 | |
| Days payables outstanding | 92.89 | 79.87 | 74.06 | 33.93 | 66.48 | |
| Days of inventory on hand | 141.01 | 176.34 | 141.18 | 116.08 | 192.84 | |
| Receivables turnover | 5.63 | 3 | 5.68 | 5.86 | 3.03 | |
| Payables turnover | 3.93 | 4.57 | 4.93 | 10.76 | 5.49 | |
| Inventory turnover | 2.59 | 2.07 | 2.59 | 3.14 | 1.89 | |
| ROE | 0.13 | 0 | 0 | 0.04 | -0.01 | |
| Capex per share | -189.24 | -140.24 | -98.77 | -118.7 | -107.42 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 487.74 | 445.16 | 414.78 | 475.11 | 497.78 | |
| Net income per share | 4.35 | 16.17 | 1.09 | -3.98 | -27.97 | |
| Operating cash flow per share | 28.07 | 16.17 | 1.09 | -47.82 | -32.03 | |
| Free cash flow per share | 25.63 | -48.97 | -18.27 | -75.34 | -66.84 | |
| Cash per share | -62.08 | 192.48 | 25.27 | -47.6 | 2.06K | |
| Book value per share | 1.3K | 1.43K | 1.48K | 1.43K | 1.45K | |
| Tangible book value per share | 1.27K | 1.64K | 1.69K | 1.64K | -421.77 | |
| Share holders equity per share | 1.3K | 1.43K | 1.48K | 1.43K | 1.45K | |
| Interest debt per share | 1.62K | 1.49K | 1.4K | 1.46K | 1.47K | |
| Market cap | 6941.59B | 6026.09B | 5137.45B | 4338.66B | 4477.72B | |
| Enterprise value | 15090.89B | 11986.3B | 11549.96B | 11515.42B | 11687.72B | |
| P/E ratio | 71.76 | 16.77 | 212.49 | -48.98 | -7.19 | |
| Price to sales ratio | 2.56 | 2.44 | 2.23 | 1.64 | 1.62 | |
| POCF ratio | 44.52 | 67.1 | 849.96 | -16.31 | -25.14 | |
| PFCF ratio | 48.76 | -22.16 | -50.64 | -10.35 | -12.04 | |
| P/B Ratio | 0.96 | 0.76 | 0.63 | 0.55 | 0.56 | |
| PTB ratio | 0.96 | 0.76 | 0.63 | 0.55 | 0.56 | |
| EV to sales | 5.57 | 4.85 | 5.01 | 4.36 | 4.22 | |
| Enterprise value over EBITDA | 52.64 | 28.22 | 56.53 | 60.7 | 138.7 | |
| EV to operating cash flow | 96.79 | 133.47 | 1.91K | -43.29 | -65.61 | |
| EV to free cash flow | 106.01 | -44.07 | -113.84 | -27.48 | -31.44 | |
| Earnings yield | 0 | 0.01 | 0 | -0.01 | -0.03 | |
| Free cash flow yield | 0.02 | -0.05 | -0.02 | -0.1 | -0.08 | |
| Debt to equity | 1.23 | 1.02 | 0.93 | 1.01 | 0.99 | |
| Debt to assets | 0.48 | 0.4 | 0.38 | 0.39 | 0.89 | |
| Net debt to EBITDA | 28.43 | 14.03 | 31.38 | 37.83 | 85.56 | |
| Current ratio | 1 | 1.06 | 1.09 | 1.03 | 0.03 | |
| Interest coverage | 1.19 | 2.89 | 1 | 0.85 | 0.03 | |
| Income quality | 6.45 | 1 | 1 | 12.01 | 1.3 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.48 | 0.13 | 0.21 | 0 | -0.03 | |
| Sales general and administrative to revenue | 0.04 | 0.03 | 0.04 | 0.04 | 0.04 | |
| Research and developement to revenue | 0.01 | 0 | 0 | 0 | 0.01 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Capex to operating cash flow | -0.09 | -4.03 | -17.79 | 0.58 | 1.09 | |
| Capex to revenue | -0.01 | -0.15 | -0.05 | -0.06 | -0.07 | |
| Capex to depreciation | -0.1 | -1.56 | -0.87 | -1.04 | -1.29 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 356.64 | 722.48 | 190.22 | 357.92 | 954.56 | |
| ROIC | 0.01 | 0.01 | 0 | 0 | 0 | |
| Return on tangible assets | 0 | 0 | 0 | 0 | -0.02 | |
| Graham Net | -1.54K | -1.08K | -1.19K | -1.29K | 921.64 | |
| Working capital | -14.84B | 470.57B | 671.9B | 225.27B | 8547.82B | |
| Tangible asset value | 7065.73B | 9115.23B | 9377.77B | 9143.33B | 2346.04B | |
| Net current asset value | 4364.33B | 2513.28B | 2243.48B | 2537.66B | 10817.22B | |
| Invested capital | 1.23 | 1.02 | 0.93 | 1.01 | 0.99 | |
| Average receivables | 2285.98B | 2767.53B | 2976.92B | 3022.4B | 3636.9B | |
| Average payables | 826.16B | 1047.21B | 1041.28B | 1158.91B | 1240.67B | |
| Average inventory | 2718.44B | 2997.06B | 3320.33B | 3587.47B | 3608.91B | |
| Days sales outstanding | 78.54 | 115.44 | 108.7 | 111.1 | 130.39 | |
| Days payables outstanding | 54.14 | 70.21 | 61.49 | 71.59 | 58.2 | |
| Days of inventory on hand | 152.67 | 203.64 | 215.72 | 199.69 | 177.33 | |
| Receivables turnover | 1.15 | 0.78 | 0.83 | 0.81 | 0.69 | |
| Payables turnover | 1.66 | 1.28 | 1.46 | 1.26 | 1.55 | |
| Inventory turnover | 0.59 | 0.44 | 0.42 | 0.45 | 0.51 | |
| ROE | 0 | 0.01 | 0 | 0 | -0.02 | |
| Capex per share | -2.44 | -65.14 | -19.36 | -27.52 | -34.81 |
KAEF.JK Frequently Asked Questions
What is PT Kimia Farma (Persero) Tbk stock symbol ?
PT Kimia Farma (Persero) Tbk is a ID stock and trading under the symbol KAEF.JK
What is PT Kimia Farma (Persero) Tbk stock quote today ?
PT Kimia Farma (Persero) Tbk stock price is $850 today.
Is PT Kimia Farma (Persero) Tbk stock public?
Yes, PT Kimia Farma (Persero) Tbk is a publicly traded company.
Company Profile
- Volume Average 5.78M
- Market Capitalization 4982.04B
- Employee 11.56K
- CEO Mr. David Utama
- Headquarters Jakarta,ID
- IPO Date 2001-07-05
-
Website
https://kimiafarma.co.id 
PT Kimia Farma (Persero) Tbk produces and sells medicines, herbal medicines, iodine, salts, quinine and their derivative products, and vegetable oils in Indonesia. The company operates through Manufacturing, Distribution, Retail, and Other Services segments. It also manufactures and sells generic, ethical, license and narcotic medicines, and over the counter medicines, health equipment, raw materials, medicines, medical devices, and cosmetics. In addition, the company distributes its products in drug to pharmacies, hospital pharmacy installation, medical center, and drug stores. The company was founded in 1817 and is headquartered in Jakarta, Indonesia.
